Treatment with belimumab in systemic lupus erythematosus does not impair antibody response to 13-valent pneumococcal conjugate vaccine

Keyphrases

• Antibody Response 100%
• Systemic Lupus Erythematosus 100%
• Systemic Lupus Erythematosus Patient 100%
• Antibody Level 100%
• 13-valent Pneumococcal Conjugate Vaccine (PCV13) 100%
• Belimumab 100%
• Post-vaccination Antibodies 60%
• Fold Increase 40%
• Prednisolone 40%
• Vaccination 40%
• Disease-modifying Antirheumatic Drugs (DMARDs) 40%
• IgG Levels 40%
• Standard-of-care Therapy 40%
• Healthy Controls 20%
• Treatment Group 20%
• High Age 20%
• Multiplex 20%
• Enzyme-linked Immunosorbent Assay (ELISA) 20%
• Revaccination 20%
• Fluorescence Immunoassay 20%
• Pre-vaccination 20%
• Phagocytosis Assay 20%
• Hydroxychloroquine 20%
• Pneumococcal Polysaccharides 20%
• Serotype-specific IgG 20%

Immunology and Microbiology

• Antibody Response 100%
• Systemic Lupus Erythematosus 100%
• Pneumococcal Vaccine 100%
• Belimumab 100%
• Vaccination Policy 87%
• Serotype 37%
• Prednisolone 25%
• Disease-Modifying Antirheumatic Drug 25%
• Monospecific Antibody 12%
• Enzyme-Linked Immunosorbent Assay 12%
• Immunoassay 12%
• Microsphere 12%
• Hydroxychloroquine 12%

Medicine and Dentistry

• Systemic Lupus Erythematosus 100%
• Antibody Response 100%
• Pneumococcus Vaccine 100%
• Belimumab 100%
• Serotype 37%
• Prednisolone 25%
• Disease Modifying Antirheumatic Drug 25%
• Group Therapy 12%
• Enzyme Linked Immunosorbent Assay 12%
• Single Drug Dose 12%
• Immunoassay 12%
• Microsphere 12%
• Polysaccharide 12%
• Hydroxychloroquine 12%